azomycin has been researched along with docetaxel anhydrous in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
Saggar, JK; Tannock, IF | 2 |
3 other study(ies) available for azomycin and docetaxel anhydrous
Article | Year |
---|---|
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Hypoxia; Docetaxel; Doxorubicin; Female; Humans; Male; Mice; Mice, Nude; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2015 |